The lowest therapeutic dose is 0.25 mg weekly, and while this is typically used as a starting dose, some people maintain this amount throughout their treatment with great success
These protocols are not off-the-shelftheyre built around our clinical experience, tailored to individual patient needs, and continuously refined with the latest scientific research
Requires medical supervision due to dosing, side effects, and safety monitoring
This analysis revealed no statistically significant increase in pancreatitis risk compared to placebo across all Mounjaro doses: 5 mg dose: Risk Ratio 2.04, 95% CI [0.2715.69], p = 0.49 10 mg dose: Risk Ratio 0.63, 95% CI [0.085.12], p = 0.67 15 mg dose: Risk Ratio 1.26, 95% CI [0.364.98], p = 0.72 In simpler terms, this means that no dose of Mounjaro showed a clear increase in pancreatitis risk compared to taking a placebo